Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.

@article{Bauer1999LithiumAI,
  title={Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.},
  author={Michael Bauer and S Dopfmer},
  journal={Journal of clinical psychopharmacology},
  year={1999},
  volume={19 5},
  pages={
          427-34
        }
}
The addition of lithium to the treatment regimens of previously nonresponding depressed patients has been repeatedly investigated in controlled studies. The authors undertook this meta-analysis to investigate the efficacy of lithium augmentation of conventional antidepressants. An attempt was made to identify all placebo-controlled trials of lithium augmentation in refractory depression. Only double-blind studies that involved participants who had been treated with lithium or placebo addition… Expand
Lithium augmentation therapy in refractory depression—Update 2002
TLDR
Lithium is the foremost and most well-documented augmentation strategy in refractory depression and should be considered a first-line treatment strategy in patients with major depression who do not adequately respond to standard antidepressants. Expand
Lithium’s Emerging Role in the Treatment of Refractory Major Depressive Episodes: Augmentation of Antidepressants
TLDR
Augmentation of antidepressants with lithium is currently the best-evidenced augmentation therapy in the treatment of depressed patients who do not respond to antidepressants. Expand
Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.
TLDR
Lithium augmentation in the continuation phase of treatment of unipolar major depressive disorder effectively protects patients against a relapse. Expand
Review: lithium augmentation increases treatment response in refractory depression
TLDR
A meta-analysis of placebo-controlled studies on lithium augmentation in treatment-resistant depression and its applications in patients with refractory depression. Expand
Lithium Augmentation Therapy in Refractory Depression: Clinical Evidence and Neurobiological Mechanisms
  • M. Bauer, M. Adli, +4 authors T. Bschor
  • Psychology, Medicine
  • Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2003
TLDR
Augmentation of antidepressants with lithium is the best-documented augmentation therapy in the treatment of refractory depression and emerging data from animal studies suggest that the 5-HTergic system is involved in the augmentatory effect of lithium. Expand
Antidepressant augmentation and combinations.
  • C. Dording
  • Medicine
  • The Psychiatric clinics of North America
  • 2000
TLDR
Very few controlled, double-blind trials show consistently positive results for the other augmentation strategies, although some open-labeled trials and case reports are promising. Expand
How Long Should the Lithium Augmentation Strategy be Maintained? A 1-Year Follow-up of a Placebo-Controlled Study in Unipolar Refractory Major Depression
TLDR
Study data suggest that active medication should be maintained for at least 1 year after successful lithium augmentation in patients with unipolar major depressive disorder. Expand
Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression.
BACKGROUND The efficacy of lithium augmentation in therapy-resistant depression has been shown in a series of well-designed, placebo-controlled studies. However, little is known about the predictorsExpand
A systematic review of treatments for refractory depression in older people.
TLDR
Half of the participants responded to pharmacological treatments, indicating the importance of managing treatment-refractory depression actively in older people. Expand
Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression
TLDR
There is little evidence to guide the management of depression that has not responded to a course of antidepressants, and large pragmatic trials are needed to inform clinical practice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.
TLDR
Patients in this study were treated with a lower dose of lithium, the duration of conventional antidepressant therapy was longer, and they were less depressed and possibly depressed for a longer period, which suggests that lithium is indeed an effective adjunct in some patients with treatment-resistant depression. Expand
Lithium treatment and prophylaxis in unipolar depression: a meta-analysis.
TLDR
There is no reason to doubt the efficacy of lithium in the prophylaxis of unipolar depressive illness and a similar-sized effect was found for lithium when compared with placebo for uncontrolled studies. Expand
Review: lithium augmentation increases treatment response in refractory depression
TLDR
A meta-analysis of placebo-controlled studies on lithium augmentation in treatment-resistant depression and its applications in patients with refractory depression. Expand
Lithium augmentation in antidepressant-resistant patients. A quantitative analysis.
TLDR
The results support the case for lithium augmentation in treatment-resistant depression, but there remains considerable uncertainty over the duration of treatment necessary to see and sustain the treatment response. Expand
Placebo‐controlled trial of lithium augmentation of fluoxetine and lofepramine
TLDR
The authors' results confirm that LA is a useful strategy in the treatment of antidepressant-resistant depression, and the superiority of LA appears to depend on achieving adequate serum lithium levels. Expand
Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.
TLDR
The results of the double-blind part of the study and the observations during the total two-week period suggest that endogenous depression failing to respond to thymoleptic drug treatment can be improved within a short time by the co-administration of the two treatments in the indicated sequence. Expand
A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.
TLDR
This study suggests that both lithium and liothyronine may be considered as alternatives in augmenting antidepressant response in patients who do not respond to treatment with a tricyclic antidepressant. Expand
Refractory depression: A review with particular reference to the use of lithium augmentation
  • C. Katona
  • Medicine, Psychology
  • European Neuropsychopharmacology
  • 1995
TLDR
The results of a placebo-controlled trial of lithium augmentation of patients failing to respond to fluoxetine or lofepramine are presented and establish the efficacy but illustrate the difficulty of achieving adequate plasma lithium levels and the high rate of partial response to continued antidepressant alone. Expand
Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.
  • G. Stein, M. Bernadt
  • Medicine
  • The British journal of psychiatry : the journal of mental science
  • 1993
TLDR
Lithium in normal, but not in low, dose has a significant antidepressant effect in TCA-resistant depression and there was a significantly greater improvement on the MADRS for weeks 3-6 for those subjects on 750 mg lithium than for those on 250 mg lithium. Expand
Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression.
TLDR
It is concluded that lithium carbonate does augment the antidepressant effect when added to the long-term antidepressant treatment of nonresponding patients. Expand
...
1
2
3
...